Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 8/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20882881 | 0.82 | FPR2 (0.49) | FPR2PKML3MBTL1LMNANPC1 | |
| SCHEMBL14948673 | 0.80 | FPR2 (1.00) | FPR2PKMLMNA | |
| SCHEMBL22568349 | 0.65 | FPR2 (0.51) | FPR2LMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20882942 | 0.65 | FPR2 (0.66) | FPR2PKML3MBTL1LMNANPC1 | |
| SCHEMBL22568206 | 0.65 | FPR2 (0.50) | FPR2PKML3MBTL1LMNANPC1 | |
| SCHEMBL22568332 | 0.64 | FPR2 (0.50) | FPR2LMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13118219 | 0.63 | KCNT1 (0.76) | PKML3MBTL1SMN1; SMN2 | |
| SCHEMBL12994636 | 0.62 | TSHR (0.71) | LMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1275920 | 0.62 | ALDH1A1 (0.70) | L3MBTL1LMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17309967 | 0.61 | FPR2 (0.46) | FPR2PKMNPC1RAB9AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3795148-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | ALLERGAN, INC. (US) | 2021-03-24 | — | — | EP | disclosed |